Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
Recommendation
23/24 June 2026
Development / Quality Control and in vivo Relevance
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In Pharmeuropa, the “Comments concerning texts published in Issue 12.3” have been published. This provides the explanations relating to the new, revised and corrected texts adopted by the European Pharmacopoeia Commission. These include two chapters on dissolution testing:
- 2.9.42. Dissolution test for lipophilic solid dosage forms
- 2.9.43. Apparent dissolution
Both texts were previously published for comment in Pharmeuropa Issue 36.3. Further information on the changes can also be found in the PDF document published in Pharmeuropa.
The new texts will be published in Edition 12.3 of the European Pharmacopoeia in January 2026 and will be effective from 1 July 2026.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods